The USPTO’s Patent Trial and Appeal Board has denied a petition from Edward Lifesciences (EW +0.3%) for an inter partes review of U.S. Patent No. 8,057,493 held by Abbott (ABT +0.4%) subsidiary Evalve. The PTAB determined that EW had not demonstrated a reasonable likelihood that the patent’s claims are unpatentable.
The ‘493 patent covers devices, systems and methods for tissue approximation and repair at treatment sites.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.